HIGHLIGHTS
- who: Gabriele Hintzen and colleagues from the University Medical Center Groningen, Australia have published the Article: Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling, in the Journal: (JOURNAL)
- what: This approach has recently been shown to be successful in improving the antitumor activity of AFM13, an innate cell engager targeting the cell-surface CD30, in preclinical CD30+ Hodgkin lymphoma models .
- how: This review discusses EGFRtargeting therapies acting through distinct molecular mechanisms to destroy EGFR-expressing cancer cells.
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.